YC-Backed NxtCure Launches AI CRO Testing Cancer Drugs on Human Digital Twins
ycombinator · x · 2026-11-12
NxtCure Labs, backed by Y Combinator, just launched as an "AI CRO" building digital twins of humans to test cancer drugs before they reach patients. Founder Alessandro Hamm's story is striking: he was set to join YC's P26 batch to speed oncology drugs to market when he himself was diagnosed with cancer; he has since beaten it and is now building the company full-time. The team claims their approach is 28% better than even the best frontier AI models. Context: oncology trials take 10+ years, 3% of drugs get approved, and 90%+ fail post-animal testing.
Related event: YC-backed NxtCure Tests Cancer Drugs on Digital Twins(2 posts)→
More from Apps
- Kalshi partners with AnyAlpha to let AI agents trade prediction markets 24/7 — ycombinator · 2026-11-12
- Grok agent autonomously browses, orders and pays for a book on an unfamiliar site — xkonjin · 2026-11-12
- Google's Stitch Rapid: rough prompt to multi-screen flow in 5 seconds — tokumin · 2026-11-12
- Bing adds two ways to turn off AI search: a toggle extension and a "-ai" query parameter — JordiRib1 · 2026-11-12
- MKBHD spotted using Ardia, an open-source Arc alternative that cuts agent browser token use in half — BLCNYY · 2026-11-12
- Epic's 2026 AI MegaJam partners include Claude, Google, OpenAI, NVIDIA and AMD — jfischoff · 2026-11-12